The ability of cells to undergo a regulated and programed death is critical to the development and survival of multicellular organisms (Cory et al., 2003; Youle and Strasser, 2008) . Deregulation of the processes that govern this mode of cell death, known as apoptosis, has been linked to the developmental disorders and diseases, including some cancers (Horvitz, 1999) . The intrinsic apoptotic pathway is regulated, in large part, by the mitochondrial outer membrane permeabilization (MOMP); when MOMP occurs, cytochrome c is released, and downstream cysteinyl aspartate-specific proteases, called caspases become activated (Riedl and Salvesen, 2007) . Members of the B-cell lymphoma 2 (BCL2) family have the ability to regulate MOMP, positively or negatively, and are divided into two classes, pro-or antiapoptotic, based on whether they lead to MOMP (proapoptotic) or inhibit MOMP (antiapoptotic).
Since the initial discovery of BCL2, 24 additional family members have been identified based on the presence of a small amino-acid motif, known as the BCL homology domain (BH) and only six members perform antiapoptotic functions (BCL2, BCLxl/BCL2L1, BCLw/BCL2L2, BFL1/BCL2A1, MCL1 and BCLb/ BCL2L10; Lanave et al., 2004) . Although each of the six antiapoptotic BCL family members has been shown, in vitro, to inhibit apoptosis caused by various stimuli, there is mounting evidence that these proteins also perform distinct functions. The strongest support for this came from the analysis of mice engineered to lack the expression of individual BCL genes. The phenotypes of BCL-null mice range from embryonic lethality (BCLxl and MCL1), to abnormal death of sperm cells (BCLw), to no identifiable phenotype (BCLb; Youle and Strasser, 2008) .
Multiple studies have recently examined the in vitro protein-protein interactions and relative antiapoptotic abilities of all six antiapoptotic BCL family members (Chen et al., 2005; Zhai et al., 2006) . However, a comprehensive in vivo comparison of the oncogenic potential of the six BCL family members has not been reported. To date, only BCL2 and BCLxl have been shown to be bona fide oncogenes (Vaux et al., 1988; Swanson et al., 2004) . However, recent findings suggest that some BCL family members (MCL1 and BCLw) are overexpressed in human malignancies (Chen et al., 2007; Kawasaki et al., 2007; Wesarg et al., 2007) . Therefore, we decided to use a mouse model of MYC-induced leukemogenesis, in which hematopoietic progentior cells are transduced with retroviral vectors, ex vivo, followed by reintroduction into lethally irradiated sygeneic recipients. In fact, multiple groups have used variations of this, in vivo, assay to show the cooperative oncogenic potential for numerous genes, including BCL2 and MYC (Hemann et al., 2005; Luo et al., 2005) .
There are several dissimilarities among the antiapoptotic BCL family members; for instance, the amino-acid sequence identities, compared to BCL2, range from 43.8 to 22.1% (Figure 1a ). In addition, analysis using the 'SMART' algorithm indicates that although all six proteins encode at least three BCL homology domains (BH1-3), only BCL2, BCLxl and BCLw encode a fourth BH domain near the amino termini of the proteins (Schultz et al., 1998) . Furthermore, five of the family members encode recognizable transmembrane domains that would potentiate insertion into the outer mitochondrial membrane, whereas BFL1 lacks this motif. Finally, a phylogeny algorithm indicated that BCL2, BCLxl and BCLw comprise a group closer in relative evolutionary time, whereas BCLb, MCL1 and BFL1 appear to comprise a distinct evolutionary group that is less related (Figure 1b ; Larkin et al., 2007) .
Taking into consideration the levels of sequence divergence among the six BCL proteins and the observations made by others regarding subcellular localization and biochemical interactions, we decided to test whether each of the BCL genes could cooperate with MYC in leukemogenesis. Retroviruses used to infect bone marrow cells prepared from mice harboring a tetracycline transactivator (tTA)-dependent MYC allele (Tet-O-MYC), allowed for constitutive expression of the BCL gene from the provirus and tTA-dependent expression of the Tet-O-MYC transgene (Figure 1c) . Following infection ex vivo, cells were transplanted into the tail vein of lethally irradiated syngeneic recipients, and disease occurrence was monitored by the presentation of clinical signs, including lethargy, ruffled fur, a distended abdomen and occasionally hind limb paralysis ( Figure 2a ). Upon presentation of disease, usually between 20 and 90 days following transplant, mice were euthanized for further analysis.
Mice that received cells coexpressing MYC and any of the BCL genes showed accelerated tumorigenesis compared to mice that received cells that expressed either MYC and luciferase or MYC and GFP (green fluorescent protein; Figure 2a ). Although each of the BCL genes significantly cooperated with MYC to accelerate disease onset, it appeared that the three closest related genes (BCL2, BCLxl and BCLw) were the most potent, with all mice succumbing to disease within 30 days post-transplantation. Regardless of the genotype of the leukemic cells, all mice displayed organomegaly of spleen and liver, which was caused by leukemic cells disrupting the architecture of the spleen and infiltrating into the liver (Figures 2b and c) . Leukemic cells initiated by either MYC alone or MYC plus BCL genes had uniform rates of proliferation, as shown by immunohistochemistry with two markers of proliferation (phospho-histone H3 or Ki67), indicating that expression of BCL proteins did not significantly increase cellular proliferation ( Figure 2d and data not shown). In addition, multiple tumors expressing MYC þ BCL genes that were transplanted into sublethally irradiated secondary recipient mice readily formed tumors that exactly mimicked the primary malignancies. Taken together, these data indicate that the coexpression of MYC and any of the individual BCL family members increases the penetrance and decreases the latency of tumorigenesis, without significantly altering the proliferation rates, compared to the expression of MYC alone.
Although all BCL family members were capable of cooperating with MYC in leukemogenesis, it was important to determine whether the leukemic cell phenotype was altered when different BCL family members were expressed. To address this issue, we examined cell surface markers, known to be expressed on cells of either the lymphoid or myeloid lineages, from various hematopoietic tissues-spleen, thymus, lymph nodes and marrow of the long bones-by flow cytometry. Irrespective of whether tumors were initiated by MYC alone or by MYC and BCL genes, we observed a profound increase in the number of cells that express the myeloid markers Gr-1 and Mac-1 (CD11b) in the spleen and bone marrow (Figures 3a and b) . However, lymphopoiesis was not overtly perturbed in the leukemic mice, as the thymus and lymph nodes contained normal ratios of resident cells and there were no increases in the numbers of lymphoid cells in the spleen (data shown, Supplementary figure 1). As tumor cells reside primarily in the bone and spleen and express the Gr-1 and Mac-1 cell surface markers, the malignancies resemble acute myeloid leukemia (AML).
Next, we measured levels of MYC and BCL proteins in whole spleen samples by western blotting. Endogenous Myc was detected in cells of the normal spleen, with consistently increased levels of MYC protein observed in each of the tumor samples, consistent with the induction of the transgene in the tumor cells (Figure 3c ). In contrast, specific antibodies for each of the BCL proteins clearly show high levels of the respective BCL protein in the tumor samples. Only endogenous BFL1 was detected in whole spleen extracts from nonleukemic mice, consistent with earlier data showing the expression of BFL1 in the hematopoietic compartment (Mandal et al., 2005) .
To explore whether our observations using an MYCdriven mouse model of AML might be relevant to human malignancies, we measured the expression of each of the BCL genes in a panel of solid human tumors and leukemia/lymphoma cell lines. Using the 'TissueScan oncology survey panel' from Origene, we performed quantitative real-time PCR analysis on cDNA acquired from 60 different tissues and tumor For each paraffin-embedded liver section, immunohistochemistry was performed using an antibody that recognizes phosphorylated-histone H3, to identify cells in mitosis. Infiltrating leukemic cells from three random photographs were counted and the total ratio of phospho-histone H3 positive cells for all tumors of a given genotype (dark bars) or the ratio of phospho-histone H3-positive cells for each individual tumor (open bars) was determined. Analysis of these ratios using a student's t-test showed no statistically significant differences in the proliferation rates compared to MYC þ GFP tumors. BCL, B-cell lymphoma; GFP, green fluorescent protein; tTA, tetracycline transactivator. samples for all six BCL genes, plus ACTIN as a control (Figure 4a ). The panel consists of cDNA derived from five samples-three 'normal' and nine tumor samples for each tissue (breast, liver, lung, ovarian and prostrate)-deposited into individual wells. Following quantitative real-time PCR analysis, we observed elevated levels of BFL1 in eight of nine breast tumor samples (dark bars) and three of nine colon tumor samples, compared to the normal tissue controls (light bars). Increased BCL2 expression was also detected in seven of the nine breast cancer samples, and BCLxl was overexpressed in a number of ovarian tumors. BCLw was the only additional member that was highly expressed in more than two tumor samples from a particular tissue, being elevated in three lung cancer patients.
As further support for the possible implications of our in vivo mouse studies, we sought to determine whether BCL members and MYC are coexpressed in leukemia and lymphoma cell lines derived from human patients. All six BCL members were readily detectable in various human leukemia/lymphoma cell lines by western blotting with antibodies specific for each BCL protein. Importantly, MYC protein was also detected in each sample, indicating that the experiments conducted in this study, using MYC-induced murine AML, are likely pertinent to the study of human malignancies.
If BCL family members play a causal role in human neoplasms, it is important to determine whether inhibiting their antiapoptotic effects will have therapeutic benefits. It has been known for more than 10 years that the overexpression of only the BH3 domain of certain proapoptotic BCL family members is sufficient to block the activity of BCLxl and BCL2 and can cause apoptosis in cultured tumor cells (Cosulich et al., 1997; Holinger et al., 1999) . In addition, deinduction of an inducible BCL2 transgene, in the presence of a constitutive MYC allele, was sufficient to cause regression of lymphoid tumors in mice (Letai et al., 2004) . This suggested that inhibiting the function of an antiapoptotic gene (BCL2), even in the context of additional oncogenic lesions (MYC), might be sufficient to extend the lives of patients with lymphoma overexpressing BCL2.
Such studies have stimulated research designed to target the antiapoptotic machinery, and several small molecules that inhibit the antiapoptotic BCL family members by binding within the BH3 hydrophobic pocket have been identified. One of the most promising first generation molecules, ABT-737, has a very high specificity for inhibiting BCL2, BCLxl and BCLw and has shown promise against many tumor types, including leukemias and solid tumors, as a single agent and in combination with other therapies (Konopleva et al., 2006; Reed, 2006; Kohl et al., 2007; Shoemaker et al., 2008) . For instance, eight out of nine primary CD34 þ human AML samples efficiently underwent apoptosis in the presence of ABT-737, whereas three out of four normal CD34 þ stem cell samples were unaffected by the drug (Konopleva et al., 2006) . Although the bulk of the work with this compound has been in cell culture and in animal models, this molecule, along with several others, is currently being tested in clinical trials to determine safety and efficacy in patients.
BCL genes may also have a role in both primary and acquired drug resistance. For example, increased expression of BCL2, BCLxl and BCLb has been observed in AML cell lines resistant to high levels of busulfan treatment, and increased copy numbers of genomic loci encoding BCLw, MCL1 and BCLb were identified in various cell lines that were treated with, and became resistant to, etoposide, campothecin or Ara-C, respectively (Yasui et al., 2004; Valdez et al., 2008) . These data add emphasis to the findings we report here, and support the need to understand the role of all BCL genes in cancer and to consider targeting multiple members of the BCL family in both primary and drugresistant tumors. TissueScan oncology survey cDNA panels were obtained from OriGene (Rockville, MD, USA) and quantitative PCR analysis was performed (Sybr Green, Applied Biosystems, Foster City, CA, USA) using two independent oligo pairs for each BCL gene. The average level of mRNA in normal tissue samples (light bars) was used for each tissue type to determine the fold change in expression of each sample (dark bars). The average of the fold change between the two pairs of genespecific oligos was determined and the standard error of the mean is depicted. The horizontal line indicating a threefold increase in relative expression serves as a reference. (b) Antibodies specific for each BCL family member were used for western blot analysis of whole cell lysates (1% CHAPS, 150 mM NaCl, 10 mM Hepes) from multiple leukemia/lymphoma cell lines. An antibody against MYC was used to determine the levels of MYC protein, and antibodies against b-actin and tubulin were used as a loading control. BCL, B-cell lymphoma.
